ArticleFrontiers in medicine2025
Dynamic ferritin levels and survival outcomes in secondary hemophagocytic syndrome: a comprehensive analysis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Critical care outcomes of hemophagocytic lymphohistiocytosis in children: a single centre retrospective observational study.Pediatric rheumatology online journal · 2026Observational
- Early Prediction Model for Etoposide-Based Protocols Resistance in Pediatric HLH.Pediatric health, medicine and therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hemophagocytic syndrome (HPS) is a life-threatening condition characterized by excessive immune activation and cytokine release. Reliable prognostic markers to guide clinical management and predict outcomes are lacking. This study aims to evaluate the prognostic ability of dynamic ferritin levels in patients with HPS and their potential role in guiding treatment modifications. Materials and methods: We conducted a retrospective cohort study including 99 patients diagnosed with HPS between January 2013 and June 2022. Data on demographic characteristics, clinical presentations, treatment modalities, and laboratory values were collected, including ferritin levels at diagnosis and during treatment. Statistical analyses including Cox proportional hazards models were used to assess the risk factors of mortality, and a receiver operating curve analysis was conducted to assess the association between ferritin level changes and survival outcomes. Results: Patients exhibiting a decrease in ferritin levels within the first week of treatment had significantly improved survival rates compared to those with increasing levels ( Conclusion: The improved survival associated with early decreases in ferritin levels highlights the potential of ferritin monitoring to guide clinical decision-making and treatment adjustments. Based on the results, the integration of ferritin level dynamics into HPS management protocols could improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.